Eli Lilly and Novo Nordisk shares fall as CVS opts out of Medicare obesity drug coverage
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- Paradium AI (PAAI) Halted, News Pending
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
April 21, 2026 1:33 PM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,327.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "The broadening of Medicare coverage for the GLP-1 medications for obesity is a key driver of US market growth for LLYs Zepbound as weve previously discussed (see HERE and HERE). Recent commentary from UNH and CVS (see below; both stocks covered by Erin Wright) have raised some questions about the path to broader coverage via the CMS BALANCE program in 2027 following a 2026 bridge program (which begins July 1), which has... More
